市場調查報告書
商品編碼
1319144
全球光學成像市場 - 2023-2030 年Global Optical Imaging Market - 2023-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
2022 年,全球光學成像市場規模達到16 億美元,預計到2030 年將達到40 億美元,實現利潤豐厚的成長。預計在預測期內(2023-2030 年),全球光學成像市場將呈現12.4% 的年複合成長率。
光學成像利用吸收和散射等光子特性來測量和感知器官和軟組織的品質。儘管光學成像技術仍處於早期發展階段,但與目前的成像方法相比,它具有多項技術優勢。醫生利用照片診斷和治療各種疾病,科學家則利用照片開展各種研究項目。與使用電離輻射成像的核磁共振成像和X 射線相比,光學成像已被證明更加安全和高效。
對更安全、更準確的診斷儀器的渴望推動了癌症領域對無輻射光學成像技術的需求。這些方法具有即時成像、出色的解析度以及從分子水準描述組織特徵的能力等優點。
光學成像通過減少輻射照射和提供有關腫瘤生物學的重要資訊,在改善癌症檢測、診斷和治療規劃方面發揮著至關重要的作用。例如,2022 年10 月,GenWorks 推出了無輻射設備Braster Pro,這是一種易於使用的接觸式乳腺癌篩查設備,旨在通過提供早期檢測和減少輻射照射來徹底改變醫院。
光學成像技術的進步是預測期內市場成長的主要驅動力之一。光學成像技術的發展大大提高了其在醫學、生物學、材料科學等多個領域的能力和應用。
例如,2023 年3 月,CytoVeris 和佛羅里達州中部AdventHealth 合作開展了一項臨床研究,通過在手術中使用人工智慧驅動的成像設備來改善前列腺癌的治療效果。該設備名為MarginASSURE,旨在通過提供即時、準確的邊緣評估,改善手術決策和患者預後。
光學成像是一種先進的診斷工具,需要熟練的操作人員才能有效使用。然而,合格操作人員的短缺,尤其是在發展中國家,阻礙了光學成像在臨床診斷中的應用。快速變化的技術環境要求醫療服務提供者掌握操作先進成像系統的必要技能。預計在預測期內,這種延遲採用將阻礙市場的成長。
COVID-19 疫情增強了醫生和其他醫療工作者保持社交距離的必要性。受COVID-19 的影響,一些成像和診斷部門的光學成像病例量急劇下降。光學成像病例的減少對所有執業機構的短期和長期經濟生存能力都有重大影響。
根據發表在《美國放射學會雜誌》(JACR)上的一項研究,與2019年相比,在這次全球健康危機中,為期七週的總成像量減少了近28%,其中包括所有患者服務地點和成像方式類型。
據估計,俄烏衝突對全球光學成像市場的影響不大,原因是該地區的發病率較低,而且沒有主要的市場參與者。不過,在預測期內,設備進出口對全球光學成像市場成長的影響預計不大。
The global optical imaging market reached US$ 1.6 billion in 2022 and is expected to witness lucrative growth by reaching up to US$ 4.0 billion by 2030. the global optical imaging market is expected to exhibit a CAGR of 12.4% during the forecast period (2023-2030).
Optical imaging employs photon characteristics such as absorption and scattering to measure and perceive the qualities of organs and soft tissues. Despite the fact that optical imaging technology is still in its early stages of development, it offers several technological benefits over current imaging methods. Doctors use photos to diagnose and cure various disorders, while scientists use them to conduct a variety of research projects. In comparison to MRI and X-ray, which employ ionising radiation for imaging, optical imaging has been shown to be significantly safer and more efficient.
The desire for safer and more accurate diagnostic instruments drives the demand for radiation-free optical imaging techniques in cancer. These approaches have the benefit of real-time imaging, excellent resolution, and the ability to characterise tissues at the molecular level.
Optical imaging plays a critical role in improving cancer detection, diagnosis, and treatment planning by reducing radiation exposure and providing essential information about tumour biology. For instance, In Oct 2022, GenWorks introduced the Braster Pro, a radiation-free device, easy-to-use, contact-based breast cancer screening device, aiming to revolutionize hospitals by providing early detection and reducing radiation exposure.
Technological advancements in optical imaging is one of the key significant drivers that help the market to grow during the forecast period. Optical imaging technology developments have substantially improved its capabilities and use in a variety of sectors, including medicine, biology, materials science, and others.
For instance, In March 2023 CytoVeris and AdventHealth Central Florida have collaborated on a clinical study to improve prostate cancer outcomes by using AI-powered imaging devices during surgery. The device, called MarginASSURE, aims to enhance surgical decision-making and patient outcomes by providing real-time, accurate margin assessment.
Optical imaging is an advanced diagnostic tool that requires skilled operators for effective use. However, a shortage of qualified operators, especially in developing nations, hinders its use in clinical diagnostic applications. The rapidly changing technological landscape requires healthcare providers to acquire the necessary skills to operate advanced imaging systems. This delay in adoption is expected to hinder the market's growth during the forecast period.
The COVID-19 epidemic enhanced the necessity for doctors and other healthcare workers to maintain social distancing. As a result of COVID-19, several imaging and diagnostic departments have witnessed a rapid decline in optical imaging case volumes. The fall in optical imaging cases has major consequences for all practising settings' short- and long-term economic viability.
According to a study published in the Journal of the American College of Radiology (JACR), a nearly 28 per cent decrease in total imaging volume was observed during this global health crisis over a seven-week period when compared to 2019, and this included all patient service locations and imaging modality types.
The Russia-Ukraine conflict is estimated to have a moderate impact on the global optical imaging market, owing to the low prevalence and absence of key market players in this region. however, the impact of the import and export of devices is expected to have little influence over the global optical imaging market growth over the forecast period.
The global optical imaging market is segmented based on infection type, drug type, end user and region.
The optical coherence tomography from the technology segment with around (40.1%) is expected to dominate during the forecast period. Non-invasive imaging tests include optical coherence tomography (OCT) and optical coherence tomography angiography (OCTA). They capture cross-section photographs of your retina using light waves.
OCT is a non-invasive medical imaging tool that is increasingly being used in the regular examination and therapy of patients with neuro-ophthalmic diseases. Its capacity to define the optic nerve head, peripapillary retinal nerve fibre layer, and cellular layers of the macula, including the ganglion cell layer, allows for both qualitative and quantitative evaluation of optic nerve pathology.
For instance, In Sep 2022 Kubota Vision announced a collaboration agreement with Joslin Diabetes Center for their Patient Based Ophthalmology Suite (PBOS) in-home optical coherence tomography (OCT) device. The collaboration aims to evaluate the effectiveness of home-based OCT in evaluating diabetic macular edema and monitoring patients at risk for losing vision. The agreement aims to improve the quality of care for patients with diabetic macular edema.
North America is estimated to hold about 38.7% of the total market share throughout the forecast period with enormous possibilities. For instance, According to a report published in NCBI by the Department of Neurology, it is estimated that 30 million people in India suffer from neurological disorders. The optical image market is expected to grow due to the large patient pool, healthcare technology adaptation, government initiatives, and favourable insurance policies. Key players are also setting up regional headquarters and manufacturing plants in emerging economies like Singapore, China, Korea, and India, resulting in a positive growth curve in the optical imaging market.
The major global players in optical imaging include: Abbott Laboratories, Carl-Zeiss AG, Canon Inc, Danaher Corporation, Koninklijke Philips N.V, PerkinElmer Inc, Topcon Healthcare, Leica Microsystems, Visionix, Cylite Pty Ltd and others.
Product mapping available as excel consisting of key products of all the major players.
The global optical imaging market report would provide approximately 53 tables, 54 figures and 195 Pages.
LIST NOT EXHAUSTIVE